ATE — Antibe Therapeutics(Pre-Merger) Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$15.64m
- -CA$9.27m
- 24
- 46
- 12
- 17
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12.8 | -19.1 | -24.7 | -25.3 | -19.3 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 4.43 | 5.12 | 4.48 | 5.58 | 2.95 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.911 | 2.01 | 19.7 | 2.65 | -0.228 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -7.06 | -11.3 | -0.105 | -16.9 | -16.3 |
Capital Expenditures | -0.157 | -0.001 | — | -0.009 | -0.009 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.1 | -0.46 | -0.264 | -20.2 | -11.8 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.257 | -0.461 | -0.264 | -20.2 | -11.8 |
Financing Cash Flow Items | -0.845 | -0.933 | -5.61 | -0.002 | 0.159 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 9.59 | 12 | 66.2 | -0.026 | 0.08 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.27 | 0.193 | 65.8 | -37.2 | -28.1 |